BOSTON, April 23, 2025 (GLOBE NEWSWIRE) — BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced the presentation of seven presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025, in Chicago. The presentations highlight BPGbio’s advances in mitochondrial medicine, immuno-oncology, and precision diagnostics, powered by its proprietary NAi Interrogative Biology® Platform.
“We are proud of the tremendous progress across our oncology pipeline at BPGbio both in the BPM31510 and BRG399 franchises. Our NAi platform has revealed hallmark mechanistic insights into mitochondrial control mechanisms in cancer,” said Niven R. Narain, Ph.D., President and CEO at BPGbio. “Our AACR presentations reinforce the importance of stabilizing mitochondrial function and capacity in oncology drug development. BPGbio is now keenly focused on advancing our clinical data and assessing the best commercialization partners to serve patients and families.”
“The breadth of our AACR data—spanning diagnostics, drug mechanism of action, and immuno-oncology— showcases the power of BPGbio’s NAi Interrogative Biology…”
Highlights from BPGbio’s AACR 2025 presentations include:
- Clinical Progress in GBM: A Phase 2 trial of BPM31510 in newly diagnosed glioblastoma multiforme (GBM) demonstrates favorable tolerability and early signals of disease control, reinforcing its potential to address one of oncology’s toughest indications.
- Mitochondrial Reprogramming in the Tumor Microenvironment: BPM31510 remodels immune landscapes and rewires cancer metabolism, showing immune-enhancing and anti-tumor effects in an immunogenic oncology model.
- Ferroptosis-Independent Apoptosis: Data show BPM31510 induces ROS-mediated apoptosis in cancer cells without triggering ferroptosis, underscoring a novel mechanism of selective cytotoxicity.
- C6 Glioma Warburg Reversal: BPM31510 reverses the Warburg effect in quinone-deficient glioma models, restoring oxidative phosphorylation leading to tumor resolution in vivo.
- BRG399 as a Next-Generation ICD Agent: Preclinical studies show BRG399 drives potent immunogenic cell death and immune infiltration, especially at lower doses, positioning it as a strong candidate for combination immunotherapy.
- Targeting CoQ Deficiency in Cancer: Multi-omic analysis of TCGA and GTEx datasets identifies cancers with disrupted ubiquinone biosynthesis pathways, spotlighting new indications for mitochondrial-targeted therapies.
- Project Survival – Early Detection of PDAC: A 7-year, multi-site biomarker study identified a four-protein diagnostic panel that distinguishes pancreatic cancer patients from at risk populations with high sensitivity and specificity.
“This reinforces the critical importance of mitochondrial medicine and protein homeostasis in oncology and immunology to impact preclinical and clinical…”
“The breadth of our AACR data—spanning diagnostics, drug mechanism of action, and immuno-oncology— showcases the power of BPGbio’s NAi Interrogative Biology Platform to link biology to therapeutic outcomes,” said Michael Kiebish, Ph.D., Vice President, Platform and Translational Sciences at BPGbio. “This reinforces the critical importance of mitochondrial medicine and protein homeostasis in oncology and immunology to impact preclinical and clinical development leading to improved outcomes for patients.”
Presentation Details:
Abstract 1591 / 7: Mechanisms of BPM31510-induced cell death in cancer: lipid peroxidation and apoptosis pathways
Presentation: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. in Poster Section 16
Abstract 1527 / 9: Reversal of the Warburg Effect with BPM31510 treatment in a quinone deficient C6 Glioma resulting in efficacy
Presentation: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. in Poster Section 14
Abstract 3277 / 9: Investigating the link between metabolic reprogramming and immune modulation in tumors: exploring the therapeutic potential of BPM31510
Presentation: Monday, April 28, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 30
Abstract 4177 / 27: Integrated assessment of alterations in coenzyme Q biosynthesis genes impacting cancer metabolism leading to critical vulnerabilities in tumors
Presentation: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. in Poster Section 13
Abstract 5937 / 29: Development of a protein and clinical multiparametric biomarker panel for assessing pancreatic adenocarcinoma risk
Presentation: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 32
Abstract CT242 / 11: A phase 2 study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Presentation: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 51
Abstract 6161 / 13: Exploring BRG399, a novel microtubule-binding agent, as an inducer of immunogenic cell death in cancer therapy
Presentation: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. in Poster Section 40
